428 related articles for article (PubMed ID: 28818869)
1. Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases.
Arnold SD; Brazauskas R; He N; Li Y; Aplenc R; Jin Z; Hall M; Atsuta Y; Dalal J; Hahn T; Khera N; Bonfim C; Majhail NS; Diaz MA; Freytes CO; Wood WA; Savani BN; Kamble RT; Parsons S; Ahmed I; Sullivan K; Beattie S; Dandoy C; Munker R; Marino S; Bitan M; Abdel-Azim H; Aljurf M; Olsson RF; Joshi S; Buchbinder D; Eckrich MJ; Hashmi S; Lazarus H; Marks DI; Steinberg A; Saad A; Gergis U; Krishnamurti L; Abraham A; Rangarajan HG; Walters M; Lipscomb J; Saber W; Satwani P
Haematologica; 2017 Nov; 102(11):1823-1832. PubMed ID: 28818869
[TBL] [Abstract][Full Text] [Related]
2. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study.
Eapen M; Brazauskas R; Walters MC; Bernaudin F; Bo-Subait K; Fitzhugh CD; Hankins JS; Kanter J; Meerpohl JJ; Bolaños-Meade J; Panepinto JA; Rondelli D; Shenoy S; Williamson J; Woolford TL; Gluckman E; Wagner JE; Tisdale JF
Lancet Haematol; 2019 Nov; 6(11):e585-e596. PubMed ID: 31495699
[TBL] [Abstract][Full Text] [Related]
3. Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.
Mehta RS; Peffault de Latour R; DeFor TE; Robin M; Lazaryan A; Xhaard A; Bejanyan N; de Fontbrune FS; Arora M; Brunstein CG; Blazar BR; Weisdorf DJ; MacMillan ML; Socie G; Holtan SG
Haematologica; 2016 Jun; 101(6):764-72. PubMed ID: 27036159
[TBL] [Abstract][Full Text] [Related]
4. Long-term Survival after Hematopoietic Cell Transplant for Sickle Cell Disease Compared to the United States Population.
St Martin A; Hebert KM; Serret-Larmande A; Jouhet V; Hughes E; Stedman J; DeSain T; Pillion D; Lyons JC; Steinert P; Avillach P; Eapen M
Transplant Cell Ther; 2022 Jun; 28(6):325.e1-325.e7. PubMed ID: 35302009
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
[TBL] [Abstract][Full Text] [Related]
6. Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics.
Keklik F; Alrawi EB; Cao Q; Bejanyan N; Rashidi A; Lazaryan A; Arndt P; Dincer EH; Bachanova V; Warlick ED; MacMillan ML; Arora M; Miller J; Brunstein CG; Weisdorf DJ; Ustun C
Haematologica; 2018 Dec; 103(12):2109-2115. PubMed ID: 30076172
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis.
Arnold SD; Brazauskas R; He N; Li Y; Hall M; Atsuta Y; Dalal J; Hahn T; Khera N; Bonfim C; Hashmi S; Parsons S; Wood WA; Steinberg A; Freytes CO; Dandoy CE; Marks DI; Lazarus HM; Abdel-Azim H; Bitan M; Diaz MA; Olsson RF; Gergis U; Seber A; Wirk B; LeMaistre CF; Ustun C; Duncan C; Rizzieri D; Szwajcer D; Fagioli F; Frangoul H; Knight JM; Kamble RT; Mehta P; Schears R; Satwani P; Pulsipher MA; Aplenc R; Saber W
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1747-1756. PubMed ID: 32464284
[TBL] [Abstract][Full Text] [Related]
8. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.
Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140
[TBL] [Abstract][Full Text] [Related]
9. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.
McCurdy SR; Kasamon YL; Kanakry CG; Bolaños-Meade J; Tsai HL; Showel MM; Kanakry JA; Symons HJ; Gojo I; Smith BD; Bettinotti MP; Matsui WH; Dezern AE; Huff CA; Borrello I; Pratz KW; Gladstone DE; Swinnen LJ; Brodsky RA; Levis MJ; Ambinder RF; Fuchs EJ; Rosner GL; Jones RJ; Luznik L
Haematologica; 2017 Feb; 102(2):391-400. PubMed ID: 27846611
[TBL] [Abstract][Full Text] [Related]
10. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
11. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.
Inamoto Y; Kimura F; Kanda J; Sugita J; Ikegame K; Nakasone H; Nannya Y; Uchida N; Fukuda T; Yoshioka K; Ozawa Y; Kawano I; Atsuta Y; Kato K; Ichinohe T; Inoue M; Teshima T;
Haematologica; 2016 Dec; 101(12):1592-1602. PubMed ID: 27662017
[TBL] [Abstract][Full Text] [Related]
12. Matched sibling donor stem cell transplantation for sickle cell disease: Results from the Spanish group for bone marrow transplantation in children.
Benítez-Carabante MI; Beléndez C; González-Vicent M; Alonso L; Uría-Oficialdegui ML; Torrent M; Pérez-Hurtado JM; Fuster JL; Cela E; Díaz-de-Heredia C;
Eur J Haematol; 2021 Mar; 106(3):408-416. PubMed ID: 33296531
[TBL] [Abstract][Full Text] [Related]
13. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient.
Maury S; Balère-Appert ML; Chir Z; Boiron JM; Galambrun C; Yakouben K; Bordigoni P; Marie-Cardine A; Milpied N; Kanold J; Maillard N; Socié G;
Haematologica; 2007 May; 92(5):589-96. PubMed ID: 17488681
[TBL] [Abstract][Full Text] [Related]
14. Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT.
Frankiewicz A; Peczynski C; Giebel S; Harrington A; Socié G; Niederwieser D; Scheid C; Bornhäuser M; Kröger N; Elmaagacli A; Afanasyev B; Dreger P; Rössig C; Blaise D; Kratz C; Yakoub-Agha I; Kremens B; Niemeyer CM; Wulf G; Blau I; Penack O; Greinix H; Basak GW
Front Immunol; 2020; 11():1537. PubMed ID: 32793210
[TBL] [Abstract][Full Text] [Related]
15. Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation.
Gluckman E; Cappelli B; Bernaudin F; Labopin M; Volt F; Carreras J; Pinto Simões B; Ferster A; Dupont S; de la Fuente J; Dalle JH; Zecca M; Walters MC; Krishnamurti L; Bhatia M; Leung K; Yanik G; Kurtzberg J; Dhedin N; Kuentz M; Michel G; Apperley J; Lutz P; Neven B; Bertrand Y; Vannier JP; Ayas M; Cavazzana M; Matthes-Martin S; Rocha V; Elayoubi H; Kenzey C; Bader P; Locatelli F; Ruggeri A; Eapen M;
Blood; 2017 Mar; 129(11):1548-1556. PubMed ID: 27965196
[TBL] [Abstract][Full Text] [Related]
16. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcomes following bone marrow transplantation in patients with sickle cell disease: A cohort study of US Medicaid enrollees.
Mahesri M; Schneeweiss S; Globe D; Mutebi A; Bohn R; Achebe M; Levin R; Desai RJ
Eur J Haematol; 2021 Feb; 106(2):273-280. PubMed ID: 33155319
[TBL] [Abstract][Full Text] [Related]
18. Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation.
Shenoy S; Angelucci E; Arnold SD; Baker KS; Bhatia M; Bresters D; Dietz AC; De La Fuente J; Duncan C; Gaziev J; King AA; Pulsipher MA; Smith AR; Walters MC
Biol Blood Marrow Transplant; 2017 Apr; 23(4):552-561. PubMed ID: 28065838
[TBL] [Abstract][Full Text] [Related]
19. The role of adenotonsillectomy in graft-versus-host disease.
Schwab B; Raynor E
Int J Pediatr Otorhinolaryngol; 2012 Jan; 76(1):57-60. PubMed ID: 22018926
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor-alpha gene polymorphisms are associated with severity of acute graft-versus-host disease following matched unrelated donor bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium study.
Goyal RK; Lin Y; Schultz KR; Ferrell RE; Kim Y; Fairfull L; Livote E; Yanik G; Atlas M
Biol Blood Marrow Transplant; 2010 Jul; 16(7):927-936.e1. PubMed ID: 20100586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
